Vasectomy News and Research

RSS

A vasectomy is a surgical procedure that makes a man sterile, or unable to get a woman pregnant. It is generally considered to be at least as effective as female sterilization and is simpler to perform, safer, and less costly. A vasectomy is done by blocking the tube, called the vas deferens, through which sperm normally pass from each testicle on the way to the seminal vesicle, forming semen.

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Roundup: Abortion bill heads to Mich. Gov's desk; Calif. health care special session priorities; Nurse practitioner role debated in Minn.

An omnibus abortion bill, approved by the Senate on Wednesday, passed the House early this morning by a 72-35 vote, after a controversial requirement that an aborted fetus be buried, cremated or interred was removed earlier this week. Democrats offered a handful of amendments, some referred to as "what's good for the goose is good for the gander," to require men to undergo physical exams before being prescribed Viagra or to get a vasectomy. But all the amendments were shot down. Gov. Rick Snyder is expected to sign the bill into law.

14 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Roughly two in five women in the U.S. do not use any form of birth control: Survey

Roughly two in five women in the United States do not use any form of birth control and many underestimate their risk for pregnancy, according to a recent survey about contraceptive practices in the United States.

13 Sep 2012

WHO commits to fast-track assessment of new and existing quality contraceptives

WHO today committed to fast-track its assessment of new and existing quality contraceptives so more women in low- and middle-income countries can obtain and use a broader range of safe and effective contraceptive products.

12 Jul 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

UM hosts symposium on next generation characterization tools for therapeutic proteins

In a concerted effort to boost regional collaboration on developing new protein drug and diagnostics, the University of Maryland (UM) School of Pharmacy has hosted the first Interdisciplinary Symposium on Next Generation Characterization Tools for Therapeutic Proteins.

16 Apr 2012

Ga. vasectomy bill goes viral

A Democratic lawmaker has proposed denying men vasectomies as a parody of a Republican bill that would prohibit abortions for women more than 20 weeks pregnant. Elsewhere, a Wisconsin bill would require physicians to give women a physical exam and be present when giving abortion-inducing drugs.

24 Feb 2012

New research gains increased respect for contraceptive method

Imagine a contraceptive that could, with one or two painless 15-minute non-surgical treatments, provide months of protection from pregnancy. And imagine that the equipment needed were already in physical therapists' offices around the world.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Survey shows low awareness for non-surgical permanent birth control methods

A recent first-of-its-kind survey of 1,006 mothers in the U.S. showed that more than 75 percent of women reported being done having children, but only 24 percent discussed this decision with their OB/GYNs.

8 Nov 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011